Rate My Professor Olivia Wu

Professor Olivia Wu holds the William R Lindsay Chair of Health Economics at the Health Economics and Health Technology Assessment (HEHTA) unit within the School of Health & Wellbeing, University of Glasgow. She is also Adjunct Professor at the Faculty of Pharmacy, Mahidol University in Thailand, and an elected Fellow of the Royal Society of Edinburgh. Her expertise lies in health technology assessment methodologies, health economic evaluations, evidence synthesis, and clinical evaluations spanning pharmacological treatments, medical devices, diagnostic tests, and digital health interventions. This multidisciplinary research has informed clinical guidelines and health policy decisions at national and international levels. Olivia leads the Complex Reviews Synthesis Unit (CRSU), hosting one of the nine NIHR Evidence Synthesis Groups, and serves as Director of the NIHR Better Methods Better Research (BMBR) Programme and the National Research Collaboration Programme (NRCP). She chairs the REF2029 Sub-panel 2: Public Health, Health Services and Primary Care, previously served 10 years on the NICE Technology Appraisal Committee, and advises HTA agencies globally. As chief or co-investigator, she oversees active projects exceeding £50 million in value.

Professor Wu champions inclusivity, co-leading the Women in Health Economics and Outcomes Research Initiative for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and steering the NIHR Race Equity and Diversity in Careers Incubator. She mentors researchers internationally. Notable publications include 'Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis' (Health Technology Assessment, 2006), 'Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT' (Health Technology Assessment, 2021), 'Bisoprolol in patients with chronic obstructive pulmonary disease at high risk of exacerbation' (JAMA, 2024), and 'Dismantling behavioural weight management interventions: component network meta-analysis of randomised controlled trials and real-world services' (Health Technology Assessment, 2025). Her scholarship has amassed over 10,000 citations, highlighting impact in evidence synthesis, economic evaluations, cost-effectiveness analysis, and health technology assessment.